Memorial Sloan Kettering Cancer Center
ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Study of T-DXd Monotherapy and Combinations in Advanced /Metastatic HER2+ GC/GEJA: DESTINY-Gastric03
By
ASCO GI 2022 Conference Coverage
FEATURING
Yelena Y. Janjigian
By
ASCO GI 2022 Conference Coverage
FEATURING
Yelena Y. Janjigian
Login to view comments.
Click here to Login